New eye drug aims to block two causes of vision loss at once

This study tests an investigational drug called OCUL101 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision and can lead to blindness. OCUL101 targets two proteins involved in the disease to reduce abnormal blood vessel growth and inflammation. About 255 adults aged 50-89 will receive either OCUL101 or the standard treatment Eylea to see which is safer and more effective at preserving vision.